RESUMO
Hemophagocytosis is usually observed in bone marrow. But it can be an incidental finding in other body fluids in severe infections like cerebrospinal fluid in case of meningitis. Clinicians need to rule out primary type of hemophagocytic syndrome.
RESUMO
BACKGROUND: Tyrosine kinases are highly expressed in platelets and play an important role in their activation process. Some studies have reported the blocking effects of tyrosine kinase inhibitors on different platelet functions. OBJECTIVES: Evaluate the effects of nilotinib on platelets aggregation in 42 patients with chronic phase of CML and correlate the results with clinical and hematological parameters: age, complete blood count and presentation. PATIENTS AND METHODS: This study was conducted on 42 patients diagnosed as Chronic Phase of Chronic Myeloid Leukemia based on clinical, morphological and cytogenetic study. All patients were on Nilotinib treatment and were attending the National Center of Hematology in Baghdad. About 9 mL of venous blood sample were collected from each patient and control subjects, samples divided into 3 parts for complete blood count, platelet aggregation test and PT and aPTT. RESULTS: The mean age was 41.3⯱â¯1.7 (mean⯱â¯SEM) years old. M:F ratio of 1.2:1. Mean duration of nilotinib therapy(1.4 years). All patients had normal PT and aPTT.Only 16 (38%) patients had abnormal aggregation response to epinephrine, but there was no statistically significant differences with control group. CONCLUSION: Nilotinib had no adverse effect on platelet function nor patients clotting tests.
RESUMO
BACKGROUND: L-asparaginase is chemotherapeutic agent commonly used in treatment of Acute Lymphoblastic Leukemia. Thromboembolic and to a lesser extent bleeding events are serious complications associated with administration of this drug during the induction phase in ALL especially in children resulting from reduced synthesis of proteins such as Antithrombin & fibrinogen. OBJECTIVE: Evaluation of the coagulopathic side effect of L-asparaginase during the induction phase in treatment of ALL in children by measuring fibrinogen levels before & after administration of this drug. SUBJECTS & METHOD: An interventional prospective study was performed on 30 newly diagnosed children with ALL, all of them received 9 cycles of L-asparaginase during the induction phase according to UKALL 2003 Protocol. Fibrinogen was measured before & after treatment with L-asparaginase and the results are compared to a control group of 30 healthy children age & sex matched. RESULTS: Reduced fibrinogen level is observed in 13 out of 30 patients (43.3%) after treatment with L-asparaginase ranging from 25 to 110â¯mg/dl with means fibrinogen before & after treatment of 252⯱â¯16.40â¯mg/dl & 158.97⯱â¯17.88â¯mg/dl respectively (pâ¯<â¯.0001). CONCLUSION: Significant reduction in fibrinogen level occurred in childhood ALL patients after treatment with L-asparaginase.
